Verastem Oncology
Update in progressVSTM (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Verastem, Inc. is a development-stage biopharmaceutical company focused on cancer therapies. Its candidates are Avutometinib, an oral dual RAF/MEK inhibitor targeting the RAS/MAPK pathway, and Defactinib, an oral FAK inhibitor for solid tumors. The company runs trials such as RAMP 301, RAMP 201, FRAME, and RAMP 205, and collaborates with Chugai, Pfizer, Amgen, and GenFleet. Based in Needham, MA.
Company score
- Sentiment
- 0.11
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.28
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.11
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!